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Abstract Treatment of various types of cells with the
mitochondrial ATP-sensitive K? channel opener, diazox-
ide, preconditions cells to subsequent injuries and inhibits
apoptosis. However, the role and mechanism(s) of diaz-
oxide in solid tumor cell growth are largely unknown. Here
we demonstrate that diazoxide inhibited the proliferation of
lung cancer cells as well as the transcription of cell cycle-
related protein Cyclin D1. Cyclin D1 overexpression
inhibited the negative role of diazoxide in cell cycle pro-
gression. We further explored the mechanisms by which
diazoxide affected Cyclin D1 transcription and found that
the b-catenin transcription factor was downregulated by
diazoxide, with a corresponding decrease in Cyclin D1
promoter activity. Taken together, these results suggest that
diazoxide inhibits lung cancer cell proliferation via
downregulation of Cyclin D1 transcription, which may
have important therapeutic implications in lung cancer
patients.
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Introduction
In various types of cells, opening of the mitochondrial
ATP-sensitive K? (mitoK-ATP) channels leads to
enhanced resistance to subsequent injury caused by dif-
ferent stimuli, including induction of apoptosis [1–4].
MitoK-ATP channels can be selectively opened using low
doses of diazoxide [5]. Diazoxide is a potassium channel
activator, which causes local relaxation in smooth muscle
by increasing membrane permeability to potassium ions
[4–9]. Although the effect of diazoxide on isolated mito-
chondria has been thoroughly studied, the role and
mechanism(s) of diazoxide in solid tumor cell growth are
largely unknown. Therefore, the goal of our study was to
explore the morphologic and biochemical changes induced
by diazoxide in tumor cells and find out how such changes
might lead to enhanced prosurvival signaling.
One of the main properties of cancer cells is their
increased and deregulated proliferative activity [10, 11]. It
is now well known that abnormalities in many positive and
negative modulators of the cell cycle are frequent in many
cancer types, including lung carcinomas [12, 13]. Cyclin
D1, a member of the Cyclin D family, regulates the initial
G1-to-S transition by inhibiting Rb and activating E2F
proteins, and it contributes to cell apoptosis, proliferation,
and differentiation [14]. Cyclin D1 is amplified and/or
overexpressed in a number of human cancers, including
breast carcinoma and B cell and T cell malignancies, and
contributes to tumor cell growth [14–16]. Accumulated
evidence indicates that there is extensive cross-talk
between the transcriptional and posttranscriptional regula-
tion of Cyclin D1 expression and its biological functions.
In this study we examined the effect of diazoxide on
H1299 cell proliferation. Diazoxide inhibited the prolifer-
ation of H1299 cells as well as the transcription of cell
cycle-related protein Cyclin D1 via downregulation of
b-catenin transcription factor, which provided a new
mechanism of diazoxide-involved cell proliferation and
may have important therapeutic implications in lung cancer
patients.
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Restriction enzymes, bovine calf serum, RPMI-1640 med-
ium, Trizol reagent, and the mammalian expression vector
pcDNA3.0 were from Invitrogen (Carlsbad, CA, USA).
Diazoxide and aprotinin were from Sigma Chemical Co (St.
Louis, MO, USA). Anti-human-Cyclin D1, anti-human-
Cyclin D2, anti-human-Cyclin D3, anti-human-CDK4, anti-
human-CDK6, and anti-human-b-catenin antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Anti-myc and anti-actin antibodies were purchased
from Oncogene (Cambridge, MA, USA). Anti-mouse-HRP
secondary antibody and anti-rabbit-HRP secondary antibody
were purchased from New England BioLabs (Ipswich, MA,
USA). Other reagents were commercially available in China.
The enhanced chemiluminescence (ECL) assay was from
Amersham Pharmacia Biotech (Uppsala, Sweden). TaKaRa
RNA PCR Kit (AMV ver.2.1) and TaKaRa MutanBEST kit
were from TaKaRa Bio Inc. (Otsu, Shiga, Japan).
Plasmids
Expression constructs for EGFPN3, pcDNA3.1-myc-A,
pGL3Basic, and pRL-CMV were kindly provided by
Dr. Dan Liu (Shanghai Medical College of Fudan Uni-
versity). Full-length cDNA of Cyclin D1 was generated
using PCR with 0.1 lg human fetal liver cDNA library as
the template, and the primers used were primer 1 (sense)
(50-TATGGAATTCCCCAGCCATGGAA-30) and primer 2
(antisense) (50-TATGGATCCCGCCCTCAGAT-30). The
PCR product was inserted in-frame into the pcDNA3.1-
mycA vector via EcoRI and BamHI restriction sites. Clones
were sequenced to identify the right insert. A 1800-bp
fragment of the human Cyclin D1 promoter was isolated by
PCR using 1 lg human genomic DNA as the template as
previously described [17]. Reporter genes containing
sequentially truncated fragments (-1745/?18, -963/?18,
-680/?18, -420/?18, -240/?18, -160/?18, -140/
?18, and -60/?18) of the Cyclin D1 promoter region
were prepared in a similar manner. Cyclin D1 promoter
LEF1 binding-site-directed mutagenesis constructs were
derived from pGL3(-420/?18) by PCR amplification
using TaKaRa MutanBEST mutagenesis kit.
Cell Culture and Transfection
H1299 cells were purchased from Shanghai Institutes for
Biological Sciences and cultured in Dulbecco’s modified
Eagle’s medium. Cell transfection was performed with
Fig. 1 Effect of diazoxide on
the proliferation of H1299 cells.
a H1299 cells treated with
control or diazoxide (20 lM)
for 24 h were trypsinized and
plated at densities of 2 9 105
into 6-well plates (Day 0). Cell
numbers were counted every
24 h. Results represent the mean
of at least four independent
experiments; bar = SE. b BrdU
uptake assays as an index of
DNA synthesis were performed
with H1299 cells treated or not
treated with diazoxide (20 lM)
for 24 h, as described in
Methods. Results are expressed
as the mean ± SD of five
independent experiments. c
Compared to control, H1299
cells treated with diazoxide
(20 lM) for 24 h had a
markedly reduced number of
cells. d Exponentially growing
cells were treated with the
indicated concentrations of
diazoxide. H1299 cells were
stained with propidium iodide
and analyzed by flow cytometry
48 h after diazoxide exposure
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Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions.
Analysis of Cell Cycle by FACS and Western Blot
Analysis
After 48 h of transfection, adherent and nonadherent cells
were collected, washed twice in phosphate-buffered saline
(PBS), and fixed with ice-cold 70% ethanol for at least 1 h.
The fixed cells were washed and stained with propidium
iodide mixture containing 50 lg/ml propidium iodide,
0.05% Triton X-100, 37 lg/ml EDTA, and 100 U/ml
ribonuclease in PBS. After incubation for 45 min at 37C,
the DNA content was determined by quantitative flow
cytometry with standard optics of the FACScan flow
cytometer (FACStar, Becton, Dickinson, Franklin Lakes,
NJ, USA) as previously reported [18]. Western blot was
performed as previously described [19] using an antibody
to GAPDH to ensure equivalent loading.
Dual Luciferase Assay and Reverse Transcription (RT)-
PCR
Dual luciferase assay and reverse transcription (RT)-PCR
were performed as described [19]. Primers used for PCR
were as follows: Cyclin D1-F, 50-CCGTCCATGCGGAA
GATC-30 and Cyclin D1-R, 50-ATGGCCAGCGGGAA
GAC-30.
Results
Effect of Diazoxide on Cell Proliferation in H1299
Cells
We first examined the effect of diazoxide on the cell pro-
liferation of H1299 cells. Diazoxide dramatically reduced
the proliferation rate in a dose-dependent manner compared
to untreated cells (Fig. 1a). Consistent with the inhibition of
Fig. 2 Effect of diazoxide on
the expression of protein-
regulating cell cycle. a Cells
treated with diazoxide (20 lM)
for 24 h were examined for the
expression of molecules
regulating apoptosis by Western
blot analysis using specific
antibodies. GAPDH was used as
an internal control. b Cells
treated with diazoxide (20 lM)
for 24 h were examined for the
expression of molecules
regulating apoptosis by RT-
PCR using specific primers.
GAPDH mRNA expression was
used as an internal control. c
H1299 cells were transiently
transfected with Cyclin D1
promoter construct pGL3(-
1745/?18). At 24 h after
transfection, cells were treated
with vehicle or an increasing
dose of diazoxide for an
additional 24 h. The luciferase
activity values were
standardized to those observed
in nontreated samples. Each
value is the mean ± SD of at
least three independent
experiments
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cell proliferation, DNA synthesis, as determined by BrdU
incorporation, was also significantly reduced in H1299 cells
treated with diazoxide compared with that of control
(Fig. 1b). Compared to control, H1299 cells treated with
diazoxide (20 lM) for 24 h had a markedly reduced num-
ber of cells (Fig. 1c). The effect of diazoxide on the cell
cycle was determined in H1299 cells using FACS analysis.
As shown in Fig. 1d, diazoxide induced a G1 phase arrest in
a dose-dependent manner (Fig. 1d).
Diazoxide Downregulated Cyclin D1 mRNA
Expression
To address the mechanisms of diazoxide-reduced cell
growth, we investigated the effect of diazoxide on the
expression of the Cyclin D family proteins (Cyclin D1, D2,
and D3) and their corresponding kinases (CDK4 and
CDK6), which are involved in the regulation of cell cycle
progression and mitogenic signals [14, 20]. As depicted in
Fig. 2a, diazoxide downregulated the expression of Cyclin
D1 without significantly changing the expression of the
other examined proteins. Next, we performed RT-PCR to
determine the effects of diazoxide on the mRNA expression
of the Cyclin D family, CDK4, and CDK6. As depicted in
Fig. 2b, diazoxide inhibited the mRNA expression of
Cyclin D1. There were no significant differences in Cyclin
D2, Cyclin D3, CDK4, or CDK6 mRNA levels before and
after diazoxide treatment. To determine the role of diaz-
oxide in Cyclin D1 transcription, we a constructed Cyclin
D1 promoter pGL3 that contained the region from nucleo-
tide position -1745 to ?18 relative to the transcription start
codon. Transfection studies using pGL3 treated with the
indicated dose of diazoxide showed that diazoxide inhibited
the activity of the Cyclin D1 promoter in a dose-dependent
manner in H1299 cells (Fig. 2c).
Diazoxide Inhibited Cyclin D1 Transcription via
Downregulation of b-Catenin Transcription Factor
To identify the cis element responsible for the effect of
diazoxide, luciferase reporter constructs containing pro-
gressive deletion of the 1745-bp genomic DNA fragment
were generated and cotransfected into H1299 cells treated
or not treated with diazoxide. The luciferase assay showed
Fig. 3 Diazoxide downregulates Cyclin D1 promoter activity by
reducing the level of transcription factor b-catenin. a Cyclin D1-luc
constructs containing various lengths of Cyclin D1 promoter regions
were transiently transfected into H1299 cells treated or not treated
with diazoxide. Luciferase activities were measured as described
above. Normalized luciferase activity was standardized to that with
vector alone. b Reporter plasmid pGL3(-420/?21) (WT) or its LEF-
1 binding-site-mutated constructs (MUT) were transfected into H1299
cells. At 24 h after transfection, cells were treated with control or
diazoxide for 24 h. The luciferase activities were obtained and
presented as described above. c H1299 cells were treated for 24 h
with indicated dose of diazoxide and cell extracts were subjected to
immunoblot analysis using an anti-b-catenin antibody. d H1299 cells
were transiently cotransfected with pGL3(-420/?21) construct and
control vector or b-catenin expressing vector. At 24 h after transfec-
tion, cells were treated or not treated with diazoxide for 24 h.
Normalized luciferase activity was standardized to pGL3(-420/?18)
with control vector in untreated cells
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that a deletion from -140 to -60 bp resulted in a loss of
diazoxide activation (Fig. 3a).
Cyclin D1 is a key molecule in mitogenic signaling and
mediates S-phase entry from the G1 phase in the cell cycle
[15]. The Cyclin D1 promoter contains a typical T-cell-
factor (Tcf)/lymphoid-enhancer-factor (LEF)-1 binding site
and its activity is largely dependent on b-catenin [21].
Inspection of this region between -140 and -60 revealed
one identified LEF-1-binding site [22]. To investigate
whether the inhibitive effect of diazoxide upon the Cyclin
D1 promoter was mediated by the LEF-1-binding site, we
introduced site-directed mutagenesis into this LEF-1-
binding site on the pGL3(-420/?18) reporter plasmid as
previously described. It was found that the mutagenesis of
this LEF-1-binding site abolished the effects of diazoxide
on the Cyclin D1 promoter activity (Fig. 3b). In addition, a
lower level of b-catenin was observed in extracts prepared
from diazoxide-treated cells (Fig. 3c), suggesting that
diazoxide may downregulate Cyclin D1 transcription via
decreasing the b-catenin level. This conclusion was further
supported in Fig. 3d, as the stimulation of Cyclin D1
promoter activity by transient transfection with b-catenin
expression plasmids was largely blunted after diazoxide
treatment.
Cyclin D1 Overexpression Abrogated Diazoxide-
Induced G1 Arrest
Because diazoxide downregulated Cyclin D1 expression,
we wanted to determine whether Cyclin D1 played an
important role in diazoxide-induced G1 arrest. To address
this point, H1299 cells were transfected with control or
GFP-tagged Cyclin D1 plasmid (Fig. 4a). Cyclin D1
overexpression abrogated diazoxide-induced G1 arrest by
flow cytometry (Fig. 4b).
Discussion
In recent studies, the understanding of how diazoxide
inhibited cell growth in hematologic cancers has greatly
improved [5, 7, 9]. However, the mechanisms of the
diazoxide-mediated growth inhibition in solid cancer are
not well understood. The aim of our investigation was to
elucidate the role of diazoxide in cell proliferation. In this
report, we have described several observations in which the
role of diazoxide in H1299 cell growth has been implicated
by FACS assay, cell number, and Brdu incorporation. The
results of our study suggest that diazoxide may be clini-
cally useful in lung cancer patients as an adjuvant
chemotherapeutic agent.
To elucidate the molecular mechanism of the role of
diazoxide in H1299 cell growth, we have demonstrated that
diazoxide decreases the protein and mRNA expression of
Cyclin D1. Evidence of the oncogenic potential of Cyclin
D1 is provided by studies with numerous models in which
the elevated expression of Cyclin D1 shortens the G1 phase
of the cell cycle and enhances malignant transformation
[14, 23]. An overexpression of Cyclin D1 blocked diaz-
oxide-decreased H1299 cell growth, demonstrating that
Cyclin D1 plays a major role in diazoxide-inhibited cell
proliferation in H1299 cells. The limitations of our study
are listed as follows: (1) All the experiments were per-
formed with H1299 cells. Thus, it is important to show that
the results obtained represent a general phenomenon and
not a peculiarity of H1299 cells. (2) All the experiments
were performed with H1299 cells in vitro. To further
investigate the effect of diazoxide on lung cancer cell
growth, the effect of diazoxide on H1299 cell growth in
vivo should be performed using tumorigenicity assay.
Another interesting finding is that diazoxide downreg-
ulated Cyclin D1 transcription via reduction of b-catenin
transcription factor. b-Catenin is a well-known DNA-
binding nuclear protein that is widely expressed in tissues
and binds to GC box motifs in promoters of many house-
keeping genes and genes involved in growth regulation and
cancer, including p21, caspase-8, Cyclin D1, and GalT V
[24–26]. Biologically, b-catenin plays important roles in a
Fig. 4 Cyclin D1 overexpression abrogated diazoxide-induced G1
arrest. a H1299 cells were transiently transfected with control vector
or GFP-tagged Cyclin D1 expression plasmid and cell extracts were
analyzed by immunoblotting with an anti-GFP Ab. GAPDH served as
a loading control. b Control or GFP-Cyclin D1 expression plasmid
was transiently transfected into H1299 cells treated or not treated with
diazoxide. At 24 h after transfection, the DNA content of cells was
determined by propidium iodide staining and FACS analysis. The
percentage of cells in each stage of the cell cycle is shown with each
FACS profile
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wide variety of physiologic processes, including cell cycle,
hormonal activation, apoptosis, angiogenesis, and onco-
genesis [24, 27]. To our knowledge, this is the first report
that diazoxide decreased b-catenin expression, which
contributed in diazoxide-reduced Cyclin D1 transcription,
which elicited a new mechanism of diazoxide-contributed
tumor development.
In summary, this work suggests that diazoxide reduced
cell progression in H1299 cells via downregulation of
Cyclin D1 transcription in a diazoxide-dependent manner,
indicating that diazoxide is a very promising new drug for
use in H1299 cells. The molecular mechanism of the
downregulation of b-catenin mediated by diazoxide should
be next investigated.
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